English
Deutsch
Français
Nederlands
Español
Reset. Heal. Grow.
From Wall Street to the Maloca: How One Man Built a Psychedelic Concierge Service for the Stars
There's a particular kind of person who shows up to an ayahuasca retreat in their late forties carrying a duffel bag and a quiet panic. They've done the things. Built the company, raised the kids, hit the income bracket. And somewhere around the second night of ceremony, sitting cross-legged in a thatched-roof maloca somewhere in the Sacred Valley, they realize they've been chasing the wrong thing for twenty years. I've sat with a few of them. The story I want to tell you here is one of the louder versions of that script — a former investment banker who flipped his life sideways after his first cup of ayahuasca and now spends his days connecting celebrities, veterans, and curious millionaires with the plant medicines and psychedelic compounds he thinks they need. It's a useful story, even if you have zero interest in being a celebrity, because it surfaces almost every question a serious person should be asking before booking a psychedelic retreat. The short version: a guy made a small fortune in the dot-com era buying and flipping premium domain names — the kind of generic single-word URLs that became digital real estate when the internet was still figuring itself out. By any external measure, he'd won. Big house, full bank account, the works. Then around 2011, he hit what he calls a spiritual midlife crisis. The familiar one. He'd done everything the culture promised would deliver fulfillment, and the fulfillment hadn't shown up. So he flew to Peru, sat with a shaman, drank ayahuasca, and — like a lot of people in that chair — came home rearranged. That's the part of the story that interests me most, because it's not unique. I've heard versions of it from tech founders, ER doctors, divorced dads, recovering addicts, and one extremely tired oncology nurse. The plant doesn't care about your portfolio. It hands everyone the same mirror. After his first ceremony, this entrepreneur started introducing friends to plant medicine. Word spread. Actress wants to try ayahuasca? He'd organize the trip. Retired NBA player struggling with addiction? He'd recommend ibogaine in Mexico, where it's legally accessible, then a ketamine clinic back in Florida for integration. The role evolved into something he describes as a concierge — except instead of asking what kind of cuisine you're into, he's asking what kind of trauma you're carrying. Here's the thing the celebrity framing tends to obscure: this is essentially the same triage that any honest plant-medicine practitioner does with a new participant. What are you actually here for? What have you tried? What's the intent? The answers shape the recommendation — ayahuasca for the long, mythic, sometimes brutal night journey. Psilocybin for emotional softening. Ibogaine for the addiction-interrupt some research suggests it can produce. Ketamine for clinical depression that hasn't budged with anything else. Most readers reading this won't have a concierge. You'll be sifting retreat websites at midnight, comparing prices, trying to figure out whether the operation in Iquitos is legit or a tourist trap with a guy in feathers. But the framework applies anyway: start with intent, work backwards to the medicine. Let me walk through the main players in this story, because they keep getting lumped together as "psychedelics" when they're genuinely different tools. These tools overlap, but they're not interchangeable. Choosing the wrong one for the wrong reason is one of the more common mistakes I see in first-timers. This is one of the most-searched questions in the space, and it deserves a careful answer. The case for ibogaine and addiction is the strongest of the bunch. Studies and clinical observations from clinics in Mexico, Costa Rica, and elsewhere suggest a single ibogaine session can interrupt the physical dependency of opioid addiction and produce what users describe as a long, autobiographical "life review" that recontextualizes the addiction itself. It's not a cure. People do relapse. But for some, it's the first crack in a wall they've been throwing themselves at for years. Ayahuasca and psilocybin have softer evidence for addiction but stronger evidence for the underlying conditions that often drive it — depression, PTSD, chronic shame, unresolved trauma. The thinking in the field is that you're not really treating the addiction; you're treating the reason the person started self-medicating in the first place. Both can be true. People who do plant medicine work alongside therapy and a recovery community tend to fare better than those who treat the ceremony as a one-shot fix. If you or someone close to you is weighing this for serious addiction, please don't go it alone. The integration matters as much as the ceremony. Probably more. Most of the substances above remain federally illegal in the United States. That hasn't stopped a wave of legal change at the edges — Oregon's psilocybin services framework, decriminalization in cities like Denver, Oakland, and Detroit, and the slow march of FDA-approved trials for MDMA and psilocybin. In the meantime, what people actually do is travel. Peru, Costa Rica, the Netherlands (for psilocybin truffles), Mexico (for ibogaine and bufo), Jamaica (for psilocybin) — these are the destinations where the medicines are either legal, regulated, or operating in tolerated grey zones. A reputable retreat will be transparent about its legal standing. A sketchy one will dodge the question or insist you not photograph the property. Ketamine occupies its own category in the U.S. — it's a legal anesthetic, and clinics offering it off-label for depression have multiplied. At-home ketamine telemedicine has also exploded, with mixed quality. Some operations do real intake screening and pair the medicine with therapy. Others mail lozenges to anyone with a credit card and a vague symptom list. Buyer beware. If this article has nudged you closer to booking something, a few things I'd want a friend to know before they put down a deposit: What strikes me about the concierge story is how thoroughly it mirrors a cultural shift that's been building for a decade. Plant medicine and psychedelic healing have moved from countercultural fringe to wellness mainstream — sometimes too quickly, sometimes with too much hype, but moved nonetheless. Veterans with PTSD are using ketamine. Tech founders are microdosing psilocybin. A documentary about an actress drinking ayahuasca won an award at a Dutch film festival a few years back. The taboo is thinning. What hasn't changed is the part the headlines tend to skip: this work is genuinely hard. The ceremony itself is one night. The integration — the slow, unflashy practice of changing how you live based on what you saw — is the rest of your life. Anyone selling you the first without preparing you for the second is selling you a souvenir. If something in this piece resonated and you want to look at what's actually out there, a curated selection of ayahuasca and plant-medicine retreats can be browsed on our marketplace here. Take your time with the decision. The medicines aren't going anywhere, and the readiness usually arrives when it arrives — not a moment sooner.
What Drinking Ayahuasca Actually Feels Like: An Honest Account
Ask anyone who's actually done it, and you'll get the same long pause before they answer. Drinking ayahuasca isn't something you summarize at a dinner party. The brew has been making its way out of the Amazon and into Western conversation for decades now, but the gap between what people imagine and what actually happens in ceremony is enormous. If you're reading this because you're weighing whether to fly to Peru, Costa Rica, or somewhere closer to home for a retreat, you deserve a straight account — not a sales pitch and not a fever dream. So let's talk about it plainly. What does ayahuasca taste like? What does it do to your body? What does it do to your mind? And what, honestly, is the point — especially if you're someone quietly hoping a plant medicine might help with addiction, depression, or a pattern in your life that won't budge? Ayahuasca is a brew. That sounds obvious, but it's worth saying because a lot of newcomers picture a pill or a powder. It's a dark, syrupy liquid, traditionally simmered for hours — sometimes a full day — over a wood fire in the Amazon. The two main ingredients are the Banisteriopsis caapi vine (the ayahuasca vine itself) and the leaves of the chacruna shrub, though some traditions use other admixture plants. The vine contains MAO inhibitors. The chacruna contains DMT. Neither does much on its own when taken orally — your stomach would shut the DMT down before it ever reached your brain. Together, though, they unlock something that indigenous peoples of the Amazon basin figured out long before any chemistry textbook explained why it works. That's part of what makes the brew remarkable. It's a piece of pharmacology that emerged from a rainforest with tens of thousands of plant species, somehow combined in exactly the right way. Across the upper Amazon — Peru, Colombia, Ecuador, Brazil — ayahuasca is woven into healing traditions that go back generations. It's considered one of the master plants: teacher plants believed to carry intelligence, to instruct the people who drink them. You don't have to subscribe to that worldview to take it seriously. Plenty of skeptical, secular people walk into a ceremony and come out describing things they can't explain. Here's the part nobody glamorizes. It tastes terrible. Picture earth, bark, bile, and stewed coffee grounds, all warmed up. Some people compare it to swamp water. Others say burnt molasses. The point is: you don't sip ayahuasca for the flavor. You drink the cup the facilitator hands you, you set it down, and you wait. The first twenty to forty minutes are quiet. Maybe you feel a slight buzz, a heaviness in your limbs, a shift in how sounds register. Then the icaros — the sung medicine songs — begin, and somewhere underneath them, the brew starts working. People describe it differently: The purging — vomiting, sometimes diarrhea — is part of it. Western readers tend to flinch at this. In the Amazonian tradition, it's not a side effect. It's the medicine doing what it came to do, clearing what it considers ready to leave. Almost every retreat hands you a personal bucket. You'll use it. So will the person next to you. The choreography of a ceremony includes a fair amount of quiet retching, and somehow it becomes ordinary within about twenty minutes. This is the part that's hardest to describe, because language is built for ordinary experience and ayahuasca isn't ordinary. Some people see visions — jaguars, snakes, lattices of color, vast architectures of light. Others don't see much at all and instead are walked through their own memories with a clarity that's almost unbearable. A childhood scene you hadn't thought about in thirty years suddenly arrives in HD, and you understand something about it you'd never understood before. The recurring theme in honest accounts isn't fireworks. It's confrontation. Ayahuasca tends to show people what they've been avoiding. The drinker who came in hoping for cosmic union with the universe might instead spend six hours examining how they've been treating their partner. The person who came for relief from depression might be shown the specific moment, decades back, where the depression set up shop. It can be brutal. It can also be tender — many people report being held, comforted, taught. There's an old joke in this world: ayahuasca gives you what you need, not what you want. Funny because true. This is the question I get most often, and it deserves a careful answer. The short version: there is real, growing evidence that ayahuasca and other psychedelics can support addiction recovery — but it's not a magic eraser, and the people who do best treat the ceremony as the beginning of work, not the end of it. Studies out of Brazil, Canada, and Spain have followed people who used ayahuasca in ceremonial contexts and tracked reductions in problem drinking, cocaine use, and tobacco dependence. Clinical trials with psilocybin for alcohol use disorder have shown encouraging results. Ibogaine, another plant-derived psychedelic from West Africa, has decades of underground use treating opioid addiction, with some clinics now operating legally in Mexico and Costa Rica. What seems to happen, across these substances, is twofold. First, there's a neurological reset — the brain becomes briefly plastic, old patterns loosen, new connections form. Second, and arguably more important, people see their addiction differently. They see what it cost them. They see what they were medicating. They see a version of themselves not yoked to the substance, and they remember that version exists. Whether that change holds depends on what they do in the months that follow. None of this is a substitute for medical care if you're in a serious addiction situation. Ayahuasca interacts badly with SSRIs, MAOIs, and certain heart and blood pressure medications. People with personal or family histories of psychosis or bipolar disorder are generally screened out by responsible retreats. If you're considering plant medicine for addiction, talk to a doctor who won't dismiss the conversation, and choose a retreat with real medical screening, not a questionnaire someone glances at over email. The plant-medicine world has matured, but it's still uneven. For every excellent center run by experienced facilitators and indigenous-trained shamans, there's a glossy website hiding a sketchy operation. Here's what experienced retreat-goers actually look for: Trust your gut on this one. If a retreat's marketing feels more like a wellness brand than a serious medicine container, keep looking. The dieta — the period of dietary and lifestyle restriction before ceremony — isn't optional. Most retreats ask you to cut alcohol, recreational drugs, red meat, pork, fermented foods, processed sugar, and sexual activity for one to two weeks before arrival. Some include cilantro, aged cheese, and a long list of medications. This isn't religious theater. The MAO inhibitors in the vine genuinely interact with tyramine-rich foods and many pharmaceuticals, and the dieta is partly a safety measure. It's also psychological preparation. By the time you arrive, you've already changed your habits. You've already noticed how much you reach for wine at night, or sugar after lunch, or scrolling at 11pm. The brew hasn't started yet and you're already learning. Afterward — and this matters more than the ceremony itself, in my opinion — comes integration. The week or month after a strong ayahuasca experience can feel raw, lit up, sometimes destabilizing. People reconsider jobs, relationships, where they live. Some of these reconsiderations are wise. Some are the medicine talking before it has fully settled. Good practice is to wait a month or two before making any irreversible decision, and to work with an integration therapist or sober friend who can help you sort signal from noise. Honest answer: maybe. Ayahuasca isn't for everyone, and the romanticization of it has done some real damage. People with certain medical conditions shouldn't drink it. People in active crisis often need stabilization before any psychedelic work. People looking for a quick fix tend to come back disappointed — or worse, more lost than they started. But for someone genuinely curious, willing to do the preparation, willing to do the integration, and clear-eyed about the risks — yes, an ayahuasca retreat can be one of the more meaningful weeks of your life. Many people come home with a softer relationship to their own pain, a clearer sense of what matters, and, sometimes, real changes in patterns they'd written off as permanent. Plant medicine isn't a religion, and it isn't a pharmaceutical, and it doesn't need to be either to be worth taking seriously. If you've read this far and something in you is still leaning toward the door marked maybe, take that seriously too. A range of carefully vetted ayahuasca retreats can be browsed on our marketplace here — useful for comparing locations, lineages, and what each container actually offers before you commit. Whatever you decide, decide slowly. The vine has been here for a very long time. It'll wait.
The Argentine Psychoanalyst Who Took Ayahuasca to the Couch in 1959
Most of the names that get repeated in the current wave of psychedelic history belong to men, and most of them lived north of the equator. So it's worth slowing down for a figure who tends to get edited out of the story: a woman in Buenos Aires who, in the late 1950s, was running LSD-assisted group sessions with food and music in the room — and who flew into the Amazon in 1959 to drink ayahuasca with curanderos before almost anyone in Western medicine had even heard the word. Her name was Luisa Agusta Rebeca Gambier de Álvarez de Toledo. Her colleagues called her Rebe. She was the first woman to preside over the Argentine Psychoanalytical Association, and she happens to have written one of the earliest scientific reports on ayahuasca published outside the Amazon. For readers interested in the deep roots of plant medicine and psychedelics in clinical practice — and how master plants found their way into the modern conversation about addiction, trauma, and soul exploration — her story is essential reading. To understand why Argentina, of all places, became fertile ground for early psychedelic experimentation, you have to understand what the city looked like in the 1940s. After the Spanish Civil War and then the Second World War, Buenos Aires absorbed waves of European intellectuals, doctors, artists, and analysts fleeing fascism. The Argentine Psychoanalytical Association was founded in 1942 in that hothouse of imported ideas, and Freud, Klein, Lacan, and the British object-relations school all got argued over at the same dinner tables. Álvarez de Toledo trained as a physician and got drawn into psychoanalytic theory while still in medical school. By the early 1950s she was working at the Hospicio de la Mercedes, the country's first psychoanalytic institution, alongside the legendary psychiatrist Enrique Pichon-Rivière. Her 1954 paper on the emotional life of the therapist during the session — what we'd now recognise as a precursor to modern conversations about countertransference and presence — is still cited as a classic. She wasn't a fringe figure. She was the establishment. And then, almost as soon as she became APA president in 1956, she organised a working group to experiment with LSD. Sandoz was the source. A representative from the Swiss company supplied the substance and the existing clinical literature, which by then included scattered reports from Europe and a handful of American hospitals. She wasn't even the first in Argentina to publish on it — the psychiatrist Alberto Tallaferro had already documented more than a thousand sessions with LSD and mescaline in 1956, and he sat in on her early work. What's striking, reading her four published articles from 1957 to 1960, is how modern the protocol sounds. The therapists drank the medicine themselves first — sometimes LSD, sometimes mescaline — and wrote up their own experiences in the scientific papers. They considered self-experimentation an ethical prerequisite, not a sideshow. You couldn't sit with a patient through something you hadn't met yourself. She brought two things into the session that weren't standard psychoanalytic furniture: She also refused to leave patients alone. The therapist's job was to build and hold a strong connection — what she'd been arguing for years was the heart of any good analytic relationship, just intensified by the medicine. By 1960, after three years of work, she was running twelve groups, around a hundred patients in total, and concluded that group psychotherapy combined with LSD was, in her words, a really effective method. She also insisted on two facilitators per group, so that if someone went into what she called a generalised psychopathic episode, one therapist could step out with them while the other held the room. Sound familiar? It's the same staffing logic any honest psychedelic retreat uses today. Then came the part of her story that almost nobody outside specialist circles knows. In 1959, Álvarez de Toledo travelled into the Amazon jungle to drink ayahuasca with curanderos. In 1959. Before Burroughs and Ginsberg's Yage Letters had reached a wide audience. Before the Santo Daime had crossed any borders. Before the word ayahuasca meant anything at all to most physicians. She published her account in 1960 as one of the very first scientific articles on the brew. Her method was a hybrid that feels surprisingly contemporary — part ethnography (she wanted to document what the curanderos actually did, in their own terms), part clinical evaluation (she wanted to know whether this could do therapeutic work). She researched how the curanderos understood the experience and what they expected of participants before she ever lifted a cup. She ended up trying ayahuasca twice with two different curanderos. The first ceremony she dismissed almost immediately — the brew had been cut with gasoline (yes, really), the room was small and dirty, the village too close and too noisy. The second time was different. Held in the forest. A curandero who treated her as a colleague and refused payment. She asked specifically to be included in a local group ceremony so she could observe how these things actually unfolded in their natural setting, rather than as a private demonstration for a foreign doctor. Her own description of the experience is worth quoting because it's so unguarded — a trained analyst writing without any of the defensive posture you'd expect from a 1960 medical journal: The curandero himself vomited, she noted, as an invitation to the others. This worried her — in her psychoanalytic frame, vomiting and diarrhea were defensive responses to the fear of the unknown. The villagers reassured her. Then her own nausea came, dry and without release, and the trance took her over completely beneath the icaros being sung around her. Walking back to the village afterwards, she described seeing the earth and plants and her own body emitting bluish waves spreading outward, lights appearing and going out around her, a deep euphoria in the presence of such beauty. She walked, uncertain, on a very soft earth. Her clinical summary afterwards was characteristically honest: she felt the observation had been disturbed by her own defenses and by her lack of the ritual language, which prevented her from fully grasping what the masters were actually doing therapeutically. She wasn't claiming mastery. She was naming the gap. It's easy to read history like this as colourful background, but it bears directly on choices people are making right now. The current wave of interest in plant medicine for addiction, depression, and trauma sometimes presents itself as brand new. It isn't. Álvarez de Toledo and her colleagues had already worked out, three generations ago, several of the principles that any reputable retreat should still be following: What strikes me, reading her papers now, is how much of the current psychedelic-assisted therapy world is reinventing wheels she'd already drawn. The careful preparation. The continuous presence. The integration sessions. The respect for group dynamics. She got there in heels in Buenos Aires in 1957 and confirmed it under icaros in the Amazon in 1959. Álvarez de Toledo died in 1990, just as MAPS was being founded in California and the modern revival was beginning to stir. She didn't live to see ayahuasca become an international phenomenon, didn't watch psilocybin trials at Johns Hopkins, didn't read the headlines about ibogaine for opioid addiction. But the through-line is hers as much as anybody's: a working clinician who took these substances seriously as therapeutic tools, treated traditional knowledge as knowledge rather than folklore, and held herself to the same rigour with mescaline and ayahuasca that she held herself to with her analytic patients. For anyone weighing whether to sit in ceremony, her example offers something more useful than enthusiasm. It offers a standard. Does the place you're considering treat preparation seriously? Are the facilitators trained, present, and willing to talk about their own relationship with the medicine? Is there real integration support afterwards? Those questions aren't new. They've just been waiting for us to ask them again. If reading this has sharpened your curiosity, a range of carefully vetted ayahuasca and plant-medicine retreats can be explored on our marketplace here — a useful place to start when you want to see what genuinely thoughtful facilitation looks like in practice today.
Ibogaine for Addiction Recovery: What the First Month After Treatment Really Feels Like
People keep asking me what the first month after ibogaine is actually like. Not the ceremony. Not the visions. The part nobody films — the slow weeks afterward when you're back in your apartment with the same fridge and the same phone and the same brain trying to figure out who you are now. That's the part that decides whether the medicine worked. Ibogaine has a strange reputation in the plant medicine and psychedelics world. It doesn't promise bliss. It doesn't sell you a sunset on Instagram. What it does — and what a growing pile of clinical research keeps confirming — is interrupt opioid dependence with a force that nothing else in the pharmacy can match. For people stuck in addiction, that interruption can feel like the first quiet room they've stood in for years. But quiet rooms are not the same as healing, and the month after is where that distinction gets brutal. The short version: the physical withdrawal piece is mostly gone. The cravings, for many people, drop to a whisper. The honeymoon window — what underground providers sometimes call the “grey period” — usually lasts somewhere between three and six weeks. During that stretch, the dopamine system is essentially reset, and the obsessive pull of the substance feels muted in a way that's almost disorienting. The longer version is messier. You sleep badly for the first ten days or so. Your appetite swings. You feel emotionally raw in a way that has nothing to do with the drug you stopped using and everything to do with the feelings you used the drug to avoid. Old memories surface uninvited. Conversations with people you haven't thought about in a decade replay themselves at 3 a.m. The medicine doesn't hand you a clean slate — it hands you the unedited footage and says good luck. What surprises most people is how physically tired they remain. Ibogaine is hard on the body. Heart rhythm, electrolytes, liver — these are not small things, which is why any reputable clinic screens you with an EKG and bloodwork before they'll touch you. Recovery from the session itself can take two to three weeks. You're not bouncing back into the gym on day five. Yes, cravings come back. Not always, not for everyone, but if you're going into this thinking ibogaine is a one-and-done cure, please recalibrate before you spend the money. What it gives you is a window. A real one. Inside that window, the compulsion that ran your life is dialed down enough that you can finally do the work — the therapy, the lifestyle rebuild, the friend group surgery, the boring daily structure — that long-term recovery actually requires. People who use the window well tend to stay clean. People who treat the trip as the finish line tend to relapse, sometimes within two months, sometimes within two weeks. This is one of the most consistent patterns in the underground and clinical data both. That's also why the better clinics insist on aftercare. Some build in booster sessions of iboga (the milder, plant-form cousin) at the 30- or 60-day mark. Some pair you with an integration coach. Some send you home with a structured plan covering sleep, nutrition, movement, meetings, and therapy. If a provider is happy to dose you and wave goodbye, that's a red flag the size of a billboard. I get asked constantly how ibogaine compares to ayahuasca or psilocybin for addiction recovery. Honest answer: they do different jobs. If you're physically dependent on opioids right now, ibogaine is probably the conversation to be having. If you've been clean for a year and you're trying to understand why you got there in the first place, ayahuasca or psilocybin may be the better match. People sometimes do both, in sequence, with months of integration between them. There's no universal map. Integration is the unsexy word for the work that turns a psychedelic experience into a changed life. After ibogaine, it tends to look something like this: Most relapses I've seen happen because someone skipped step three. The medicine bought them a clean runway and they used it to coast instead of to build. Ibogaine has killed people. Not many, but enough that you need to take the screening seriously. The deaths almost always involve undetected heart conditions, dangerous drug interactions (methadone is a particular issue — most clinics require a switch to short-acting opioids weeks in advance), or facilities that lack proper medical monitoring. A legitimate provider will require: a recent EKG, a full blood panel, a detailed medical history, a psychiatric screening, and ideally an in-person medical team during the session itself. They will not take cash from someone who walked in off the street that morning. If anything in that list is missing from the clinic you're considering, walk away. The savings are not worth your life, and the cheap options in this space are cheap for grim reasons. It's also worth saying out loud that ibogaine is not legal in the United States. The retreats people travel to are typically in Mexico, Costa Rica, the Netherlands, or other jurisdictions where the legal status is permissive or grey. Plan accordingly — passport, insurance, someone at home who knows where you are and when to expect contact. For the right person, in the right circumstances, with the right preparation and aftercare — yes, often dramatically so. I've talked to people whose lives genuinely turned a corner after ibogaine. I've also talked to people who spent twelve thousand dollars and were using again by spring. The difference between those two outcomes is rarely about the medicine. It's about everything that surrounded it. If you're considering this seriously, give yourself at least three months of research and preparation before booking anything. Talk to people who've done it. Read the underground forums with a critical eye — the loudest voices are usually either evangelists or skeptics, and the truth tends to live in the quieter middle. For readers who want to compare reputable options side by side, a curated selection of ibogaine and broader plant-medicine retreats can be explored on our marketplace here. Whatever you decide, decide it with your eyes open — the window ibogaine offers is real, and it's also temporary, and what you do with it is the whole game.
How to Store Magic Mushrooms and Truffles So They Stay Potent
So you’ve got a stash of magic mushrooms or truffles sitting on the counter, and the question creeps in: how long will these things actually last? It’s a fair worry. Psilocybin is a delicate molecule, and the way you treat your mushrooms in the days and weeks after you get them holds them is the difference between a meaningful experience later on and a damp bag of disappointment. Whether you’re saving them for a planned ceremony, a microdosing protocol, or just want a small reserve in the cupboard, storage matters more than most people realise. This is a quick, no-nonsense walk through how to keep psilocybin mushrooms and truffles in good shape — what works, what wrecks them, and how long you can realistically expect them to stay potent. None of it is complicated. But the small details make a real difference. Psilocybin and its cousin psilocin are the two compounds doing the heavy lifting in any psychedelic mushroom or truffle. Both are organic molecules, and like most organic molecules they degrade over time — slowly when conditions are right, alarmingly fast when they aren’t. Heat, light, oxygen, and moisture are the four enemies. Hand a fresh truffle all four at once and it’ll be mush within days. The goal of good storage is simple: slow the degradation as much as possible. You can’t stop it entirely. Even perfectly stored dried mushrooms lose a little potency every month. But the gap between “stored well” and “stored badly” is enormous. We’re talking the difference between mushrooms that still hit reliably a year later and mushrooms that taste like wet cardboard and barely register after a fortnight. Fresh psilocybin mushrooms and truffles are mostly water — somewhere around 90% by weight, sometimes more. That moisture is exactly what makes them so fragile. Bacteria love it. Mould loves it. Enzymes inside the mushroom itself happily keep breaking things down even after harvest. If you’re planning to use them within a week or two, the fridge is your friend. Keep them in their original packaging if it’s vacuum-sealed, or transfer them to a paper bag inside a sealed container. Paper absorbs excess moisture; pure plastic traps it and invites rot. Aim for the main body of the fridge rather than the door, where temperatures swing every time someone reaches for the milk. Realistic shelf life for fresh truffles in the fridge: about a month if they were sealed properly at the source, maybe two to three weeks once opened. Fresh mushrooms are even shorter — a week, perhaps two if you’re lucky. Check them regularly. If you see fuzzy white or green spots that aren’t the mushroom’s natural mycelium, or if anything smells sour or ammoniated, throw them out. Psychedelic curiosity is not worth a hospital trip for food poisoning. If you want mushrooms or truffles to last longer than a few weeks, drying is non-negotiable. Properly dried psilocybin mushrooms can hold most of their potency for a year or more in good conditions. Some experienced users report usable potency at two or three years, though there’s a steady downward slope. The trick is to dry them properly — to what people in the cultivation world call “cracker dry.” That means the stems snap cleanly when bent rather than folding. Anything softer, anything that bends like leather, still has too much moisture and will eventually mould. A few methods work well: Avoid the oven. People try it; people regret it. Most home ovens run far too hot at their lowest setting and you’ll cook off a meaningful chunk of the active compounds before you realise. Once they’re cracker dry, the storage rules become straightforward. You want darkness, cool temperatures, low humidity, and minimal exposure to oxygen. An airtight glass jar in a dark cupboard is the classic answer and still one of the best. For longer storage, you can level up: What about light? Direct sunlight is the fastest way to wreck psilocybin. UV rays break the molecule apart with brutal efficiency. Even a bright kitchen shelf is asking for trouble over months. Dark cupboard, drawer, or opaque container — pick one and stick to it. Magic truffles, the underground sclerotia of certain psilocybe species, behave a bit differently from above-ground mushrooms. They’re denser, hold moisture more stubbornly, and are harder to dry evenly without specialist equipment. Most people using truffles consume them fresh from a sealed package within the printed shelf life — usually a couple of months refrigerated, unopened. You can dry truffles, and they’ll keep similarly to dried mushrooms once you do, but the process is slower and you need to slice them thinly to get even drying. If you’re not set up for this, sticking with fresh truffles and using them within their fridge window is the simpler route. Your senses are reliable here. Healthy dried mushrooms smell faintly earthy and almost like old hay. Anything sharp, sour, ammonia-like, or actively unpleasant means something has gone wrong — usually moisture creeping in and feeding bacteria or mould. Visible mould in any colour is a hard stop. So is a slimy or sticky texture in something that should be brittle. Loss of potency is harder to spot visually. Mushrooms that have slowly degraded over a couple of years often look fine but simply don’t hit the way they used to. If you’re returning to an old stash, start with a smaller dose than you remember being effective and see where you land. This applies double if you’re using mushrooms for any kind of intentional inner work — not knowing your dose is one of the easiest ways to turn a meaningful evening into an unnecessarily rough one. Psilocybin remains a controlled substance in many countries, and the legal status of mushrooms, truffles, spores, and grow kits varies wildly depending on where you live. Storage advice is technical, not legal — please look up your own jurisdiction before assuming anything. And while keeping your stash fresh is useful, it’s worth asking why you’re storing it in the first place. Mushrooms aren’t snacks. If you’re sitting on a meaningful supply with no clear plan for using it, that’s often a sign that working with a facilitator or a structured retreat setting would serve you better than another solo trip in the living room. People who use psychedelics most productively tend to do so with intention, support, and integration — not because they happened to have some in the cupboard. For readers who feel ready to take the experience deeper than what a home stash can offer, a curated selection of psilocybin and plant-medicine retreats can be browsed on our marketplace here. Whatever you decide, store what you have well — fresh, dark, cool, and dry — and treat it with the respect any real medicine deserves.
Craving More Stories?
Join our ShopAyahuascaRetreats newsletter for the latest updates on thrilling
destinations and inspirational tales, delivered straight to your inbox!
We value your privacy. Your email address will never be shared or published.
The History of Psychedelics: From Cave Paintings to Plant Medicine Retreats
The history of psychedelics is older than most religions, older than written language, and — depending on which cave painting you trust — possibly older than agriculture itself. That matters. If you're reading this because you're weighing a ceremony or a retreat, it helps to know that ayahuasca, peyote, psilocybin, and the rest aren't a wellness trend invented last Tuesday. They're part of a long, messy, beautifully human story about people trying to understand consciousness, heal sickness, and reckon with what some traditions call the master plants. This is a tour through that story. We'll move from prehistoric murals to Spanish conquistadors, from a Swiss chemist's bicycle ride to the modern psychedelic research labs at Johns Hopkins. Along the way, I'll point out where the trail goes cold, where the science gets interesting, and what it all means for someone considering plant medicine for addiction, depression, or the slower kind of stuck that doesn't have a name yet. The deepest archaeological trail leads to a cave in the Tassili-N-Ajjer plateau in the Algerian Sahara. Painted on its rock walls, somewhere between 7,000 and 9,000 years old, is a figure researchers nicknamed the “mushroom shaman” — a bee-headed character with mushrooms growing out of his body. Scholars believe the species depicted is Psilocybe mairei, a psychedelic mushroom native to North Africa. Take a moment with that. People were painting their visions on cave walls before anyone built a pyramid. Across the Atlantic, the evidence is just as old. In the Rio Grande region of what's now Texas, peyote specimens dating back to roughly 3,700 BC have been analysed for mescaline content. The conclusion was straightforward: Indigenous North Americans recognised the psychoactive properties of peyote at least 5,700 years ago. In northern Peru, a stone carving from around 1,300 BC shows a deity clutching a San Pedro cactus — another mescaline-bearing plant still used in ceremony today. Further south, in Mexico and Guatemala, archaeologists have unearthed carved “mushroom stones” dated between 1,000 and 1,500 BC, widely interpreted as ritual objects connected to psilocybin use. And in 2019, researchers described a 1,000-year-old shaman's pouch found in southwestern Bolivia, containing snuffing tablets, a snuffing tube, and chemical residues of bufotenin, DMT, and harmine. That last combination is significant — harmine plus DMT is the basic pharmacology of ayahuasca. Whether the brew itself is that old, we can't quite prove. But the molecules were in the right pouch. Europe didn't go looking for psychedelics. They stumbled into them, usually while trying to convert or conquer the people who already had a relationship with these plants. The earliest written record comes from 1496, when Friar Ramon Pane — travelling with Columbus on his second voyage — described how the Taino of the Caribbean used a snuff called cohoba, made from a DMT-containing shrub. He didn't approve. He documented it anyway. Sixty-odd years later, the Spanish missionary Bernardino de Sahagún catalogued Aztec use of peyote and psilocybin mushrooms in his Florentine Codex. In the 1570s, the conquistador-physician Francisco Hernández recorded the Aztec use of ololiuqui, the seeds of a morning glory species containing LSA — a close chemical cousin to LSD. The Aztecs had their own pharmacology, fully developed, and the Spanish chroniclers preserved it, often while condemning it. It took until 1851 for ayahuasca to enter the Western written record. The English botanist Richard Spruce, exploring the upper Amazon, watched the Tukano people drink the brew and — to his credit — tried it himself. Thirteen years later, the French physician Griffon du Bellay reported iboga use in Gabon and the Congo, describing the root that would, more than a century later, become central to a particular kind of addiction recovery work. Some of the early Western encounters with psychedelics were intentional. Others were, let's say, agricultural accidents. In 1799 in London, a man went out to pick mushrooms for his family's breakfast and brought home a fistful of Psilocybe semilanceata by mistake. The whole family had what is almost certainly the first medically documented psilocybin experience in Britain. Their doctor was, by all accounts, baffled. From there, things turned more deliberate. In 1887 a Texas physician named J.R. Briggs published an account of his own peyote self-experiment. In 1893, the Comanche chief Quanah Parker handed over 50 pounds of dried peyote buttons to a Smithsonian ethnologist, and some of that material ended up in the hands of the philosopher William James. In 1897, the German pharmacologist Arthur Heffter isolated mescaline and swallowed 150 milligrams of it — the first known human experience with a purified psychedelic compound. He took careful notes, which was very on-brand for a nineteenth-century chemist. Then came 1943. Albert Hofmann, a Swiss chemist at Sandoz Laboratories, accidentally absorbed a trace of a compound he'd synthesized five years earlier and called LSD-25. A few days later, on April 19th, he ingested 250 micrograms on purpose, hopped on his bicycle to ride home, and changed the trajectory of twentieth-century neuroscience. That bike ride still gets celebrated as Bicycle Day. The man lived to 102, which is either a coincidence or a hell of an endorsement. The 1950s and early 60s were a strange, productive window. Researchers ran more than a thousand clinical studies on LSD, exploring its potential for alcoholism, depression, end-of-life anxiety, and what we'd now call PTSD. Psilocybin was synthesised by Hofmann in 1958 and quickly entered psychiatric research. For a moment it looked like Western medicine might genuinely fold these compounds into its toolkit. Then the culture turned. The compounds escaped the lab, became woven into the counterculture, and by 1970 the U.S. Controlled Substances Act had placed LSD, psilocybin, mescaline, and DMT into Schedule I — meaning, officially, no medical use and high abuse potential. Most of the world followed. Research funding evaporated. Several promising therapeutic threads simply got cut, mid-experiment. A handful of underground therapists kept working quietly. Almost everyone else moved on. This is the part of the story that's worth pausing on if you're considering plant medicine today. The reason your doctor probably can't prescribe psilocybin for your depression isn't that the science failed. It's that the science was halted, politically, for roughly forty years. We are still catching up. Somewhere around the late 1990s, the door cracked open again. Roland Griffiths' team at Johns Hopkins published carefully designed psilocybin studies showing durable reductions in depression and end-of-life distress. MAPS pushed MDMA-assisted therapy for PTSD through phase 3 trials. Imperial College London opened a dedicated Centre for Psychedelic Research. Ibogaine clinics opened in Mexico, working specifically with opioid and stimulant addiction. Ayahuasca retreats — once a rumour passed between travellers in Cusco hostels — became something a software engineer in Berlin might book on her phone. The research now points in directions that would have made Hofmann nod. Psilocybin shows real promise for treatment-resistant depression. Ibogaine appears, in observational studies, to interrupt opioid cravings in a way nothing else does. Ayahuasca has been studied for its effects on the default mode network — the brain circuitry associated with rumination and rigid self-narrative. The mechanism isn't magic. It looks more like a temporary loosening of mental ruts, with a window afterward where new patterns can take hold. That window is what serious facilitators call integration, and it's where the real work happens. A few practical things worth knowing if you're considering a retreat: Here's the honest version. The plants and compounds we now call psychedelics have been part of human life for thousands of years, used by people who took the work seriously and built elaborate frameworks around it. The West discovered them late, studied them briefly, banned them in a panic, and is now slowly, awkwardly remembering what older cultures already knew. The current renaissance isn't a discovery. It's a homecoming with paperwork. If you're considering plant medicine for addiction, trauma, or that quiet kind of depression that doesn't make a scene but rearranges your whole life — you're stepping into a tradition with deep roots, not a wellness fad. Knowing the history doesn't tell you whether a retreat is right for you. It does tell you that the question deserves more than a weekend's research. Talk to people who've done it. Read about the specific medicine you're drawn to. Find facilitators who can describe their lineage and their screening process in plain language. If something here speaks to you, the ayahuasca, psilocybin, and ibogaine retreats discussed across the broader plant-medicine world can be browsed on our marketplace here. Take your time. These plants have waited 9,000 years; they'll wait a few more weeks while you choose well.
What a Psilocybin Mushroom Trip Actually Feels Like: Inside the Experience
Picture a quiet room with a soft couch, books on the shelves, fresh flowers on a side table. It looks like somebody's living room. It isn't. It's a clinical research suite where, over the past decade, people facing terminal cancer, treatment-resistant depression, and lifelong anxiety have swallowed a capsule of psilocybin and waited for something to happen. That image — the couch, the eye shades, the careful researchers sitting nearby — has become the modern face of psychedelics. And it's a long way from the tie-dye stereotype most people still carry around. If you're reading this because you're curious about what a psilocybin journey actually feels like, or because you're weighing a psilocybin retreat for your own reasons, you deserve a clear, honest picture. Not the marketing version. The real one. One of the most consistent things people report — and one of the least talked-about in glossy write-ups — is that the experience often begins with panic. Not always. But often. A wave of anxiety swells up within thirty to sixty minutes of swallowing the capsule, and for some people it gets loud before it gets quiet. I've sat with people coming up on psilocybin in ceremonial settings, and there's a recognizable arc. The body tightens. The breath shortens. Old, half-buried thoughts surge to the surface uninvited. One participant in an early NYU study described it as physical pain that slowly revealed itself to be emotional pain — layers of grief and worry she hadn't realized she was carrying. She cried for hours. And then, eventually, the crying stopped, and something else moved in. This pattern matters because a lot of first-timers interpret the early panic as a sign they made a terrible mistake. They didn't. The discomfort is, for many, the actual work. A skilled facilitator's job in those moments isn't to make the fear stop. It's to help you stay with it long enough for it to move. Once the initial wave passes, the experience tends to widen. People describe geometric patterns blooming behind closed eyelids — gears, stars, latticework in colors that don't quite exist in waking life. Sound can take on texture. Music becomes architectural. Time bends. One young man in the same NYU trial described being carried through a series of vivid scenes: watching his own funeral in a cemetery, then dancing with his partner in Grand Central Terminal, then dropping into the sewers beneath the city, then rising to the top of the Empire State Building to watch the sun come up. None of it literal. All of it, for him, deeply meaningful. He came out of the session changed in a way he could feel but couldn't quite explain. This isn't a slideshow. It's closer to a guided lucid dream that pulls images from your own life and shows them back to you in unexpected combinations. Some people meet versions of themselves they'd forgotten. Some people sit with people they've lost. Some people feel — and this is the word that comes up over and over — connected. To other people. To the natural world. To something they don't have language for. The science is catching up to the experience, slowly. Brain-imaging studies have found that psilocybin temporarily loosens the brain's usual organizational patterns and lets regions that don't normally talk to each other start talking. The visual cortex chats with the auditory cortex — which is probably part of why people report seeing sound or hearing color. The default mode network, the part of the brain associated with rumination and self-referential thought, quiets down. Researchers at King's College London described depression as a brain stuck in a loop — the same negative thoughts circling the same well-worn tracks. Psilocybin, the theory goes, breaks the loop. For a few hours, the brain reorganizes itself. And in that window, people sometimes get a glimpse of themselves outside the loop they've been trapped in for years. Clinical work on psilocybin for end-of-life anxiety, treatment-resistant depression, and addiction has produced results striking enough that the FDA designated it a breakthrough therapy. That doesn't mean it's a cure. It means the evidence is strong enough to take seriously. Here's where the honest part comes in. Psilocybin isn't a pleasure trip, and the people who get the most out of it usually aren't chasing one. The folks I've watched benefit most are people who arrive with a specific question, a specific weight, a specific stuck place. They aren't expecting magic. They're hoping for movement. It's also not for everyone. A short list of people for whom this is genuinely risky: If you're outside those categories and you're considering a retreat for depression, addiction recovery, or simply because you've felt stuck for a long time, the next question is where to go and who to sit with. That matters more than the dose, more than the location, more than almost anything else. Reputable psilocybin retreats — legal ones operate in places like the Netherlands, Jamaica, Mexico, and parts of the U.S. where local laws have shifted — share a few things in common. Worth knowing before you book: Costs vary wildly. A solid week-long psilocybin retreat in a legal jurisdiction typically runs somewhere between two and six thousand dollars, depending on accommodation, group size, and how much wraparound care is included. Cheaper than that, and something is usually being cut. Much more than that, and you're paying for branding. One thing nobody quite prepares you for: the experience doesn't end when the substance wears off. People often describe a kind of afterglow in the first few days — softer, more open, less reactive. Then real life shows up again, and the question becomes whether you can hold on to whatever you learned when the alarm clock and the inbox come back. This is where integration earns its keep. Talking to a therapist who understands psychedelics. Journaling. Time in nature. Quiet. The insights from a psilocybin journey are fragile in the way dreams are fragile — strong while you're in them, slippery once you step back into ordinary time. Writing things down in the first 48 hours helps. So does deliberately reorganizing some small piece of your daily life around what you learned. People who treat the journey as a one-time event tend to drift back to where they were within a few months. People who treat it as the beginning of a longer conversation with themselves tend to get more out of it. The medicine opens a door. You still have to walk through it. Psilocybin isn't a shortcut. It's not a replacement for therapy, for community, for the slow work of changing a life. It can be a powerful catalyst, and for some people it's been the thing that finally cracked open a years-long depression or a pattern of addiction that nothing else could touch. For others, it's been a strange, difficult few hours that didn't deliver the breakthrough they'd hoped for. Both outcomes are real. Going in with realistic expectations — and with the right people around you — is what tips the odds toward the kind of experience worth having. If something here has stirred your curiosity and you want to look at what's actually out there, a selection of vetted psilocybin retreats can be browsed on our marketplace here. Take your time with the decision. The medicine will still be there when you're ready.
Ibogaine in Mexico for Opioid Addiction: What Recovery Actually Looks Like
Picture someone who has been on opioids for ten years. Not casually. Not recreationally. Daily, with all the architecture of a life built around the next dose — the planning, the lying, the slow narrowing of what feels possible. Now picture that same person flying to Tijuana or Playa del Carmen, sitting in a clinic bed, and swallowing a capsule made from the root bark of a West African shrub. Within hours, the withdrawal that should have crushed them for two weeks is mostly gone, and they're watching their own life unspool in front of them like an old film reel. That's the ibogaine story in its compressed form. It sounds like marketing copy. It isn't, exactly — there's real science behind it, and there are also real risks, real costs, and a whole category of things nobody warns you about until you're three days in and the visions have stopped but your nervous system feels like it's been turned inside out. If you're researching ibogaine for addiction recovery, you deserve the unsanitized version. Ibogaine is a Schedule I substance in the United States. That single legal fact is the reason an entire ecosystem of clinics has grown up along the Mexican coast and border, plus pockets in Costa Rica, Portugal, and a few other jurisdictions where the molecule sits in a legal grey area. Mexico doesn't formally regulate ibogaine, which has produced both legitimate medical clinics with cardiologists on staff and, frankly, some operations you wouldn't want your dog to detox at. The draw is specific. Ibogaine, derived from the iboga plant traditionally used by the Bwiti people of Gabon, appears to do something genuinely unusual to opioid dependence — it interrupts the withdrawal cycle and resets opioid receptor sensitivity in a way that no other single intervention reliably does. People walk in physically dependent on heroin, fentanyl, methadone, or oxycodone and walk out, days later, without the cravings that defined their lives. Not everyone. But enough that the testimonials keep stacking up. The other reason people go: desperation. Most ibogaine seekers have tried the standard menu — Suboxone tapers, methadone maintenance, twelve-step programs, inpatient rehab, sometimes multiple times. Ibogaine is what you look at when conventional addiction medicine hasn't held. A reputable clinic will not just hand you a capsule. The protocol typically starts days before the dose itself, with bloodwork, an EKG, liver panels, and a careful review of every substance in your system. This matters more than people realize — ibogaine can prolong the QT interval in the heart, which is the technical way of saying it can cause fatal arrhythmias in people with the wrong cardiac profile. The deaths that have happened in the ibogaine world have, overwhelmingly, happened in settings where this screening was skipped. The flood dose itself — the big therapeutic dose — usually lands you in bed for somewhere between 12 and 36 hours. The first phase is the visionary one. People describe panoramic life reviews, encounters with deceased relatives, dialogues with what feels like their own subconscious laid bare. The traditional Bwiti framing calls iboga a teacher, and even Western recipients who came in skeptical tend to walk out describing the experience as instructional rather than recreational. It is not, by any account, fun. The second phase is quieter. The visions fade, the body feels heavy and strange, sleep doesn't come for another day or two, and the mind keeps processing. This is where the work happens — where the relationship to the drug, the patterns underneath the using, the things avoided for years come up for examination. The third phase, which extends for weeks afterward, is often called the afterglow: a window of unusual clarity and reduced craving that participants describe as their best chance at rebuilding. This is the question people ask last and should ask first. Real medical ibogaine treatment in Mexico runs, on average, between $6,000 and $15,000 for a full program. The wide range reflects real differences: Anything priced significantly below that range should raise questions. Ibogaine is expensive to source, cardiac monitoring equipment isn't cheap, and qualified medical staff cost money. A $2,500 program is almost certainly cutting one of those corners, and the corner being cut is usually the one that keeps you alive. People researching plant medicine for addiction often end up comparing ibogaine and ayahuasca, and the comparison deserves honesty. Both are master plants. Both have been used in traditional healing contexts for generations. Both have clinical evidence supporting their use in substance use disorders. They are not interchangeable. Ayahuasca works more gradually and tends to be most useful for the psychological and emotional layers of addiction — the trauma underneath, the patterns of avoidance, the relationship to self. Multiple ceremonies over a week or two of retreat is the typical container. It does not, however, reliably interrupt physical opioid withdrawal in the way ibogaine does. Ibogaine is the heavier intervention. Single dose, more medically risky, more physically intense, and uniquely effective at the receptor-reset piece that opioid dependence requires. Some people do both — ibogaine to break the physical hold, then ayahuasca work months later to address what's underneath. Others find one is enough. Neither is a magic pill, and anyone selling either as a one-shot cure is overselling. Here's where the conversation usually stops, and where it shouldn't. The treatment itself is a doorway. What you do with the next 90 days determines whether the door stays open. The afterglow is real, but it's also temporary. The window of reduced craving and emotional openness typically lasts somewhere between four and twelve weeks. During that window, the brain is unusually plastic and unusually willing to rewire around new behaviors. Without active integration work — therapy, community, exercise, sleep, sometimes follow-up plant medicine sessions — many people drift back to old patterns once the window closes. The relapse rates in studies that don't include strong aftercare are sobering. The other thing nobody mentions: ibogaine is exhausting. Most people need two to four weeks before they feel physically normal again. Energy is low, sleep is weird, emotions sit close to the surface. Going back to a high-stress job within a week of treatment is a setup for disappointment. Plan for genuine recovery time on the other side, not a triumphant return to the same life that built the addiction in the first place. If you're seriously considering ibogaine, treat the clinic search the way you'd treat surgery research. Some honest filters: Reputable operators tend to have been working for years, have a clear medical director, publish their protocols, and are willing to say no to candidates who aren't appropriate. The newer, cheaper, glossier operations are where most of the horror stories originate. It's worth being honest with yourself about what ibogaine actually does and doesn't do. It will probably get you through opioid withdrawal in a way nothing else can. It will likely give you a window of clarity and reduced craving you can use to build something different. It will not, on its own, fix the reasons you started using, repair the relationships you damaged, or hand you a new life. That part is still on you, and it's still hard. For some people, that combination is exactly what they've been missing — a circuit breaker followed by the chance to actually do the work. For others, the medical risk, the cost, or the intensity make it the wrong fit. Both answers are legitimate. The worst outcome is the one where someone treats ibogaine as a vacation cure and skips the harder months that follow. If you've read this far and something in it resonates, the next step is talking to clinicians who do this work, not booking on impulse. For readers who want to take this further, a curated selection of ibogaine and plant-medicine retreats focused on addiction recovery can be browsed on our marketplace here. Whatever you decide, decide it slowly — this is one of the few choices where the speed of the decision matters as much as the choice itself.
Ayahuasca in Canada: How Religious Exemptions Are Opening the Door to Legal Ceremony
Something quiet has been shifting in Canada. While most of the conversation about psychedelics focuses on Oregon's psilocybin program or the slow march of MDMA trials in the U.S., a small number of religious communities north of the border have been granted something genuinely remarkable: legal permission to import, possess, and serve ayahuasca. Not in a research lab. Not under emergency provisions. In ceremony. As sacrament. If you've been researching plant medicine and wondering whether your only options involve a flight to Peru or a leap of faith into the underground, this matters. It signals a shift in how a major Western government is treating a brew that contains DMT — a substance still classified as a controlled drug. And it raises real questions about what legitimate ayahuasca practice looks like, who gets to offer it, and how the rest of us should think about choosing a retreat. The federal health agency in Canada has issued five Section 56 exemptions to religious organisations, allowing their members to legally use ayahuasca — often called Daime Tea — in ceremony. The first two were granted in 2017 to congregations in Montreal. Three more followed, going to Ceu da Divina Luz do Montreal, the Église Santo Daime Céu do Vale de Vida in Val-David, Quebec, and Ceu de Toronto. These exemptions are not casual paperwork. They authorise designated members to possess, transport, import, administer, and yes, destroy the brew when it's used as part of religious practice. They last two years and can be renewed. And they exist because Canadian law allows the health minister to carve out exceptions to the Controlled Drugs and Substances Act for medical, scientific, or public-interest reasons. The churches involved trace their lineage to the Santo Daime tradition, founded in the Brazilian Amazon in the 1930s. It's a syncretic faith — a braid of Indigenous Amazonian shamanism, Christianity, and African spiritual elements — and the tea sits at its centre, the way bread and wine sit at the centre of a Catholic Mass. Jessica Rochester, who leads Céu do Montreal and shepherded one of the original exemptions through, has described the process as exhausting. More than a decade and a half of legal back-and-forth, paperwork, scientific submissions, and the slow grind of proving to a federal bureaucracy that drinking a DMT-containing brew in a ritual setting deserves the same protection as taking communion. That timeline tells you something important. These weren't loopholes. They were hard-won concessions built on a careful argument about religious freedom, public safety, and the long history of ayahuasca's ceremonial use. The churches had to demonstrate trained leadership, member screening, safe sourcing, and a clear pastoral structure. None of which, frankly, the average pop-up ayahuasca circle in a rented Airbnb can claim. Here's where it gets practical. If you're a Canadian — or anyone, really — looking at ayahuasca for help with depression, addiction, trauma, or the broader sense that something in your life has calcified and needs to crack open, you now have a slightly clearer map. There are legitimate, legal ceremonial communities operating in Canada. There are also legal ceremonial centres in Peru, Brazil, Costa Rica, and a handful of other countries where ayahuasca operates within indigenous or established religious frameworks. And then there's everything else — which is most of what's out there. The everything-else category isn't necessarily bad. Plenty of underground facilitators are skilled, ethical, and deeply committed. But the spectrum runs wide, and the further you wander from established traditions and clear oversight, the more your screening matters. A few things worth weighing when you're deciding where to sit: One of the underrated benefits of these Canadian exemptions is that they pave the way for serious study. Researchers like Brian Rush at the Centre for Addiction and Mental Health have been evaluating ayahuasca-assisted treatment programs — including one in Peru where the brew is legal — and the findings keep pointing the same direction. There's something genuinely useful happening for people struggling with depression, addiction, and PTSD. The mechanism is still being mapped. Ayahuasca seems to open access to repressed material — emotions, memories, body sensations that the daily mind keeps locked away. Combine that with the serotonergic effects of DMT and the MAO-inhibiting action of the Banisteriopsis caapi vine, and you get a state in which both the unconscious and the nervous system become unusually plastic. Therapy in the days and weeks afterwards seems to consolidate the gains. None of which is a green light for everyone. Researchers consistently warn that people with a history of psychosis, schizophrenia, or bipolar disorder should avoid ayahuasca. Certain antidepressants — particularly SSRIs and MAO inhibitors — create dangerous interactions. The medicine is powerful, and powerful tools cut both ways. Rochester has been blunt about her concern with what she calls ayahuasca tourism — the boom in retreat centres, the proliferation of weekend facilitators, the steady stream of people flying to Iquitos with a vague sense that the vine will fix them. The worry isn't snobbery. It's that the human urge to feel better now collides badly with a tradition that asks for preparation, humility, and time. The tragic cases are real. A Canadian woman died at a Peruvian retreat in 2015. Other deaths and serious incidents have followed, usually involving inadequate screening, undertrained facilitators, or participants taking medications that should never have been combined with the brew. None of this means ayahuasca is uniquely dangerous — by most measures, it's safer than alcohol — but it does mean the container matters enormously. That's part of why the Canadian exemptions are interesting beyond their immediate legal effect. They model what a regulated, accountable, community-rooted ayahuasca practice can look like. Members. Records. Trained leadership. A relationship with the law rather than a workaround of it. Whatever you think of organised religion, the Santo Daime structure offers something most weekend retreats can't: continuity. If you're sitting with the question of whether to attend a ceremony, the Canadian story offers a few useful framings. First, there's no rush. Plant medicine has been here for centuries; it will be here next year. The right time is when you've prepared — physically, emotionally, and logistically — and when you've found a setting you trust. Second, be honest with yourself about what you're hoping for. Ayahuasca isn't a vending machine. People who arrive expecting a specific outcome often get something else entirely, and the gap between expectation and experience can itself become the lesson. Come curious, not transactional. Third, talk to people who've actually done it — ideally several people, across different traditions and centres. The internet is full of glossy retreat pages and equally glossy horror stories. Real conversations with real participants will give you a calibrated sense of what's plausible, what's exaggerated, and what you might actually be walking into. For readers who want to take this further, a range of vetted ayahuasca and plant-medicine retreats can be browsed on our marketplace here. Whether you end up booking one this year or simply spend the next six months reading, talking, and preparing, the move toward legal recognition in places like Canada means the conversation is only getting more open — and the options, more grounded.
7 Types of Meditation Explained: Which Practice Fits You Best
Search “types of meditation” and you'll drown in lists. Fifteen styles. Twenty-two styles. Every blog seems to have a longer count than the last, and somewhere around the eighth bullet point, they all start to blur together. If you're new to sitting practice — or if you've tried it once, hated it, and are wondering whether you picked the wrong style — that's a real problem. So let's slow this down. There are a handful of meditation approaches that actually matter for most people, and each one solves a specific problem. Anxiety. Stress. Self-criticism. A mind that won't sit still for ninety seconds. The trick isn't to try them all — it's to match the right practice to what you're actually carrying. This is also worth saying upfront: meditation often comes up alongside conversations about psychedelics, plant medicine, and master plants. People who sit with ayahuasca or psilocybin tend to discover, sometimes the hard way, that integration without a contemplative practice is like trying to remember a dream you never wrote down. Even if you have zero interest in plant medicine, the right meditation style still rewards you. Let's get into it. Most meditation practices fall into one of a few rough families. Knowing the families first makes the specific styles easier to choose between. None of these is better than the others in the abstract. They're just different doors into the same house. What follows is the seven specific practices I'd point a new meditator toward, and who each one actually serves. If you've never meditated and you sit down expecting to wrangle your own mind into stillness, you're going to fail. That's not pessimism, that's physics. A wandering mind needs something to wander back to, and a steady voice gives it that anchor. Guided meditation is exactly what it sounds like: a teacher (live or recorded) walks you through the session. They cue your breath, point your attention, sometimes layer in soft music or a singing bowl. There are pauses, but you're rarely left alone for long. For absolute beginners, this is the on-ramp. It's also a lifesaver for people whose anxiety spikes the moment a room goes quiet. The honest downside: some people find the voice itself distracting. If a soothing narrator makes you grit your teeth, guided isn't your style and that's fine. Move on. Silent (or unguided) practice strips away the scaffolding. No music. No narrator. Maybe a teacher opens the session with an intention, then steps back. You sit. You breathe. Whatever shows up, shows up. This is a bigger ask than it sounds. Ten minutes of silence with your own mind can feel longer than an hour of guided practice, especially in the first weeks. Silent retreats — the kind that run three, seven, or ten days — push this much further. People emerge from those changed, and sometimes shaken. It's not casual. Silent practice is also where intermediate meditators tend to settle in for the long haul. Once you stop needing the voice, the silence becomes the point. Vipassana goes back about 2,500 years, to the time of the Buddha himself. The word means something close to “seeing things as they actually are.” In practice, it's a blend of two skills: samatha, which is steady attention, and vipassana, which is clear-eyed observation of whatever your attention lands on. What makes this style genuinely useful for anxiety is its core insight: most suffering comes from how we react to sensations, not from the sensations themselves. You learn to notice a thought, register it, and let it pass without grabbing on. After enough hours, this becomes a reflex outside of meditation too — in traffic, in arguments, at 3 a.m. when the brain decides to inventory every regret you've ever had. Vipassana retreats are famously intense. Ten days of silence, no phones, no eye contact, sometimes ten hours a day of sitting. Many people who sit ayahuasca or psilocybin find that prior Vipassana experience makes the journey easier — you've already built the muscle of watching difficult content without flinching. Mindfulness gets used as an umbrella term for nearly everything these days, but the actual practice is specific. You focus on the present moment — breath, body, sounds, whatever — and when the mind wanders (it will), you note it without judgment and return. The goal isn't a blank mind. The goal is a friendlier relationship with the one you've got. Ten to thirty minutes a day is enough to feel changes within a few weeks: less reactive in meetings, slower to bite at small irritations, a fractional pause between stimulus and response that didn't exist before. This is the style I'd recommend to a working professional who wants something portable and sustainable. It travels well. You don't need a cushion or an altar — though both are nice. Zazen translates roughly as “seated meditation,” and that's pretty much the whole instruction. You sit, usually facing a wall, often with eyes half-open and softly downcast. You follow the breath. Thoughts arise and pass like clouds across a sky you happen to be watching. There's no narration, no visualization, no chant. Zen practitioners sometimes call this “just sitting” — shikantaza in Japanese — and it sounds simpler than it is. The discipline is in not adding anything. No story about how the meditation is going. No grading yourself. You sit, the breath happens, time passes. Beginners can absolutely start here, but most find it easier after they've spent some time with guided or mindfulness practice first. Once you know what your wandering mind feels like, Zen gives you a clean place to keep practicing the return. If you talk to yourself the way you'd never talk to a friend, this one is for you. Metta — from the Theravada Buddhist tradition — is the systematic cultivation of warmth, first toward yourself, then toward people you love, then toward neutral strangers, and finally toward people you can't stand. That last category is where it stops being cute and starts being real work. Sessions usually involve repeated phrases: may I be safe, may I be happy, may I be at ease. The phrases feel hollow at first. After a while they don't. Something softens. Therapists sometimes recommend Metta for depression and chronic self-criticism because it does something cognitive therapy struggles to do — it changes the felt tone of how you relate to yourself. I'm grouping these because they share a basic premise: that there's a flow of energy in the body that can be directed with attention. Chakra meditation moves through seven focal points from the base of the spine to the crown of the head, often visualizing color or light at each. Qigong does something similar with breath and gentle movement, drawing from Chinese medicine's framework of qi. How you feel about this depends partly on how literal you want to be. Some practitioners describe genuine sensations of warmth and movement; others treat it as a useful metaphor for paying close attention to specific regions of the body. Both camps tend to report the same thing after enough practice: a steadier baseline, a clearer sense of when something is “off,” and — interestingly — better recall and processing of meaningful experiences, including psychedelic ones. A few honest filters to narrow it down: One more thing worth saying: meditation isn't a competition, and it isn't a personality trait. The person who sits ten minutes a day for a year will outpace the person who white-knuckles a thirty-day retreat and then quits. Consistency wins. Always has. For readers exploring how contemplative practice fits alongside plant medicine — preparing for a ceremony, integrating afterward, or simply building a steadier mind before any of that — a range of meditation-friendly plant-medicine retreats can be browsed on our marketplace here. Pick a practice, sit with it for a few weeks, and let the rest reveal itself.
Dreaming of a Psychedelic Retreat?
We have the best deals and offers from thousands of organizers all over the world! Get them into your mailbox every week!
We value your privacy. Your email address will never be shared or published.
